Lin Luping, Bivona Trever G
Division of Hematology and Medical Oncology; University of California San Francisco; San Francisco, CA USA; Helen Diller Family Comprehensive Cancer Center; University of California San Francisco; San Francisco, CA USA.
Mol Cell Oncol. 2015 Apr 27;3(1):e1021441. doi: 10.1080/23723556.2015.1021441. eCollection 2016 Jan.
RAF- and MEK-targeted therapies are approved for patients with BRAF(V600E) melanoma and under investigation in a several other tumor types, but resistance remains a major challenge. We uncovered yes-associated protein 1 (YAP1) as a mechanism of resistance to RAF-MEK inhibition in BRAF- and RAS-mutant cancers, providing a rationale for co-targeting YAP and RAF-MEK to enhance patient outcomes.
针对BRAF（V600E）黑色素瘤患者，RAF和MEK靶向疗法已获批准，并且正在其他几种肿瘤类型中进行研究，但耐药性仍然是一个重大挑战。我们发现Yes相关蛋白1（YAP1）是BRAF和RAS突变癌症中对RAF-MEK抑制产生耐药性的一种机制，这为联合靶向YAP和RAF-MEK以改善患者预后提供了理论依据。
